1
|
Volarić J, van der Heide NJ, Mutter NL, Samplonius DF, Helfrich W, Maglia G, Szymanski W, Feringa BL. Visible Light Control over the Cytolytic Activity of a Toxic Pore-Forming Protein. ACS Chem Biol 2024; 19:451-461. [PMID: 38318850 PMCID: PMC10877574 DOI: 10.1021/acschembio.3c00640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2023] [Revised: 01/16/2024] [Accepted: 01/17/2024] [Indexed: 02/07/2024]
Abstract
Enabling control over the bioactivity of proteins with light, along with the principles of photopharmacology, has the potential to generate safe and targeted medical treatments. Installing light sensitivity in a protein can be achieved through its covalent modification with a molecular photoswitch. The general challenge in this approach is the need for the use of low energy visible light for the regulation of bioactivity. In this study, we report visible light control over the cytolytic activity of a protein. A water-soluble visible-light-operated tetra-ortho-fluoro-azobenzene photoswitch was synthesized by utilizing the nucleophilic aromatic substitution reaction for installing a solubilizing sulfonate group onto the electron-poor photoswitch structure. The azobenzene was attached to two cysteine mutants of the pore-forming protein fragaceatoxin C (FraC), and their respective activities were evaluated on red blood cells. For both mutants, the green-light-irradiated sample, containing predominantly the cis-azobenzene isomer, was more active compared to the blue-light-irradiated sample. Ultimately, the same modulation of the cytolytic activity pattern was observed toward a hypopharyngeal squamous cell carcinoma. These results constitute the first case of using low energy visible light to control the biological activity of a toxic protein.
Collapse
Affiliation(s)
- Jana Volarić
- Stratingh
Institute for Organic Chemistry, University
of Groningen, 9747 AG Groningen, The Netherlands
| | - Nieck J. van der Heide
- Groningen
Biomolecular Sciences and Biotechnology Institute, University of Groningen, 9747 AG Groningen, The Netherlands
| | - Natalie L. Mutter
- Groningen
Biomolecular Sciences and Biotechnology Institute, University of Groningen, 9747 AG Groningen, The Netherlands
| | - Douwe F. Samplonius
- Department
of Surgery, Translational Surgical Oncology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
| | - Wijnand Helfrich
- Department
of Surgery, Translational Surgical Oncology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
| | - Giovanni Maglia
- Groningen
Biomolecular Sciences and Biotechnology Institute, University of Groningen, 9747 AG Groningen, The Netherlands
| | - Wiktor Szymanski
- Stratingh
Institute for Organic Chemistry, University
of Groningen, 9747 AG Groningen, The Netherlands
- Department
of Radiology, Medical Imaging Center, University
of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands
| | - Ben L. Feringa
- Stratingh
Institute for Organic Chemistry, University
of Groningen, 9747 AG Groningen, The Netherlands
| |
Collapse
|
2
|
Arunmanee W, Duangkaew M, Taweecheep P, Aphicho K, Lerdvorasap P, Pitchayakorn J, Intasuk C, Jiraratmetacon R, Syamsidi A, Chanvorachote P, Chaotham C, Pornputtapong N. Resurfacing receptor binding domain of Colicin N to enhance its cytotoxic effect on human lung cancer cells. Comput Struct Biotechnol J 2021; 19:5225-5234. [PMID: 34630940 PMCID: PMC8479544 DOI: 10.1016/j.csbj.2021.09.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2021] [Revised: 09/05/2021] [Accepted: 09/08/2021] [Indexed: 11/24/2022] Open
Abstract
Colicin N (ColN) is a bacteriocin secreted by Escherichia coli (E. coli) to kill other Gram-negative bacteria by forcefully generating ion channels in the inner membrane. In addition to its bactericidal activity, ColN have been reported to selectively induce apoptosis in human lung cancer cells via the suppression of integrin modulated survival pathway. However, ColN showed mild toxicity against human lung cancer cells which could be improved for further applications. The protein resurfacing strategy was chosen to engineer ColN by extensive mutagenesis at solvent-exposed residues on ColN. The highly accessible Asp and Glu on wildtype ColN (ColNWT) were replaced by Lys to create polycationic ColN (ColN+12). Previous studies have shown that increase of positive charges on proteins leads to the enhancement of mammalian cell penetration as well as increased interaction with negatively charged surface of cancer cells. Those solvent-exposed residues of ColN were identified by Rosetta and AvNAPSA (Average number of Neighboring Atoms Per Sidechain Atom) approaches. The findings revealed that the structural features and stability of ColN+12 determined by circular dichroism were similar to ColNWT. Furthermore, the toxicity of ColN+12 was cancer selective. Human lung cancer cells, H460 and H23, were sensitive to ColN but human dermal papilla cells were not. ColN+12 also showed more potent toxicity than ColNWT in cancer cells. This confirmed that polycationic resurfacing method has enabled us to improve the anticancer activity of ColN towards human lung cancer cells.
Collapse
Affiliation(s)
- Wanatchaporn Arunmanee
- Department of Biochemistry and Microbiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
| | - Methawee Duangkaew
- Department of Biochemistry and Microbiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
| | - Pornchanok Taweecheep
- Department of Biochemistry and Microbiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
| | - Kanokpol Aphicho
- Department of Biochemistry and Microbiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
| | - Panuwat Lerdvorasap
- Department of Biochemistry and Microbiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
| | - Jesada Pitchayakorn
- Department of Biochemistry and Microbiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
| | - Chayada Intasuk
- Department of Biochemistry and Microbiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
| | - Runglada Jiraratmetacon
- Department of Biochemistry and Microbiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
| | - Armini Syamsidi
- Department of Pharmacy, Faculty of Science, Tadulako University, Central Sulawesi 94118, Indonesia
| | - Pithi Chanvorachote
- Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
- Cell-based Drug and Health Products Development Research Unit, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
| | - Chatchai Chaotham
- Department of Biochemistry and Microbiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
- Cell-based Drug and Health Products Development Research Unit, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
| | - Natapol Pornputtapong
- Department of Biochemistry and Microbiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
- Center of Excellence in Systems Biology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
- Corresponding author.
| |
Collapse
|
3
|
Metzger KF, Padutsch W, Pekarsky A, Kopp J, Voloshin AM, Kühnel H, Maurer M. IGF1 inclusion bodies: A QbD based process approach for efficient USP as well as early DSP unit operations. J Biotechnol 2020; 312:23-34. [DOI: 10.1016/j.jbiotec.2020.02.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2019] [Revised: 02/04/2020] [Accepted: 02/26/2020] [Indexed: 12/20/2022]
|
4
|
Pore-forming toxins from sea anemones: from protein-membrane interaction to its implications for developing biomedical applications. ADVANCES IN BIOMEMBRANES AND LIPID SELF-ASSEMBLY 2020. [DOI: 10.1016/bs.abl.2020.02.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
5
|
Critical Issues in the Development of Immunotoxins for Anticancer Therapy. J Pharm Sci 2019; 109:104-115. [PMID: 31669121 DOI: 10.1016/j.xphs.2019.10.037] [Citation(s) in RCA: 58] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2019] [Revised: 09/23/2019] [Accepted: 10/21/2019] [Indexed: 12/16/2022]
Abstract
Immunotoxins (ITs) are attractive anticancer modalities aimed at cancer-specific delivery of highly potent cytotoxic protein toxins. An IT consists of a targeting domain (an antibody, cytokine, or another cell-binding protein) chemically conjugated or recombinantly fused to a highly cytotoxic payload (a bacterial and plant toxin or human cytotoxic protein). The mode of action of ITs is killing designated cancer cells through the effector function of toxins in the cytosol after cellular internalization via the targeted cell-specific receptor-mediated endocytosis. Although numerous ITs of diverse structures have been tested in the past decades, only 3 ITs-denileukin diftitox, tagraxofusp, and moxetumomab pasudotox-have been clinically approved for treating hematological cancers. No ITs against solid tumors have been approved for clinical use. In this review, we discuss critical research and development issues associated with ITs that limit their clinical success as well as strategies to overcome these obstacles. The issues include off-target and on-target toxicities, immunogenicity, human cytotoxic proteins, antigen target selection, cytosolic delivery efficacy, solid-tumor targeting, and developability. To realize the therapeutic promise of ITs, novel strategies for safe and effective cytosolic delivery into designated tumors, including solid tumors, are urgently needed.
Collapse
|
6
|
Kheirandish MH, Jaliani HZ, Rahmani B, Nikukar H. Specific targeting of a pore-forming toxin (listeriolysin O) to LHRH-positive cancer cells using LHRH targeting peptide. Toxicon 2019; 164:82-86. [DOI: 10.1016/j.toxicon.2019.04.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2019] [Revised: 04/01/2019] [Accepted: 04/12/2019] [Indexed: 11/26/2022]
|
7
|
Zhang L, Cao Y, Liu M, Chen X, Xiang Q, Tian J. Functional recombinant single-chain variable fragment antibody against Agkistrodon acutus venom. Exp Ther Med 2019; 17:3768-3774. [PMID: 30988762 DOI: 10.3892/etm.2019.7348] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2016] [Accepted: 04/11/2018] [Indexed: 11/06/2022] Open
Abstract
Agkistrodon acutus bites are conventionally treated with animal-derived antivenom, the use of which is limited due to allergic reactions and serum sickness. Thus in the present study, the genes of humanized antibodies produced in response to A. acutus venom were extracted from lymphocytes from patients bitten by A. acutus. A single-chain variable fragment (scFv) library against venom was constructed using a T7 phage display system. ScFv genes that exhibited high affinity to venom were selected by library biopanning. An expression system was constructed for antivenom scFv fused with 6×His tag at its N- and C-terminus using pET-28a (+) vector. The scFv proteins could achieve functional and soluble expression in Escherichia coli via the auto-induction method. The purity and activity of the scFv genes and proteins were confirmed by SDS-PAGE, western blotting and ELISA. The results indicated that three soluble scFv proteins exhibited specific affinity to A. acutus venom and were harvested via the auto-induction method.
Collapse
Affiliation(s)
- Lei Zhang
- Department of Emergency, Southwest Hospital of the Third Military Medical University, Chongqing 400038, P.R. China
| | - Yuliang Cao
- Department of Emergency, Southwest Hospital of the Third Military Medical University, Chongqing 400038, P.R. China
| | - Minghua Liu
- Department of Emergency, Southwest Hospital of the Third Military Medical University, Chongqing 400038, P.R. China
| | - Xiangyu Chen
- Department of Emergency, Southwest Hospital of the Third Military Medical University, Chongqing 400038, P.R. China
| | - Qiang Xiang
- Department of Emergency, Southwest Hospital of the Third Military Medical University, Chongqing 400038, P.R. China
| | - Jun Tian
- Department of Emergency, Southwest Hospital of the Third Military Medical University, Chongqing 400038, P.R. China
| |
Collapse
|
8
|
Mutter NL, Soskine M, Huang G, Albuquerque IS, Bernardes GJL, Maglia G. Modular Pore-Forming Immunotoxins with Caged Cytotoxicity Tailored by Directed Evolution. ACS Chem Biol 2018; 13:3153-3160. [PMID: 30278129 PMCID: PMC6243392 DOI: 10.1021/acschembio.8b00720] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
![]()
Immunotoxins are proteins containing
a cell-targeting element linked
to a toxin that are under investigation for next-generation cancer
treatment. However, these agents are difficult to synthesize, chemically
heterogeneous, expensive, and show toxicity toward healthy cells.
In this work, we describe the synthesis and characterization of a
new type of immunotoxin that showed exquisite selectivity toward
targeted cells. In our construct, targeting molecules were covalently
attached or genetically fused to oligomeric pore-forming toxins. The
activity of the immunotoxin was then caged by fusing a soluble protein
to the transmembrane domain and activated via cleavage with furin,
which is a protease that is overexpressed in many cancer cells. During
the several coupling steps, directed evolution allowed the efficient
synthesis of the molecules in E. coli cells, as well
as selection for further specificity toward targeted cells. The final
construct showed no off-target activity, while acquiring an additional
degree of specificity toward the targeted cells upon activation. The
pore-forming toxins described here do not require internalization
to operate, while the many protomeric subunits can be individually
modified to refine target specificity.
Collapse
Affiliation(s)
- Natalie L. Mutter
- Groningen Biomolecular Science & Biotechnology Institute, University of Groningen, 9747 AG, Groningen, The Netherlands
| | - Misha Soskine
- Groningen Biomolecular Science & Biotechnology Institute, University of Groningen, 9747 AG, Groningen, The Netherlands
| | - Gang Huang
- Groningen Biomolecular Science & Biotechnology Institute, University of Groningen, 9747 AG, Groningen, The Netherlands
| | - Inês S. Albuquerque
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028, Lisboa, Portugal
| | - Gonçalo J. L. Bernardes
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028, Lisboa, Portugal
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom
| | - Giovanni Maglia
- Groningen Biomolecular Science & Biotechnology Institute, University of Groningen, 9747 AG, Groningen, The Netherlands
| |
Collapse
|
9
|
|
10
|
Akbari B, Farajnia S, Zarghami N, Mahdieh N, Rahmati M, Khosroshahi SA, Barzegar A, Rahbarnia L. Construction, expression, and activity of a novel immunotoxin comprising a humanized antiepidermal growth factor receptor scFv and modified Pseudomonas aeruginosa exotoxin A. Anticancer Drugs 2017; 28:263-270. [PMID: 27861173 DOI: 10.1097/cad.0000000000000452] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Overexpression of epidermal growth factor receptor (EGFR) plays a significant role in the development and metastasis of many solid tumors. Strategies based on anti-EGFR immunotoxins have shown promising results in several studies, but immunogenicity of antibody and toxin moieties is a limitation of this type of therapeutics. In the present study, a novel humanized anti-EGFR immunotoxin (huscFv-PE25) was developed by genetic fusing of a humanized anti-EGFR single-chain variable fragment (huscFv) with a modified Pseudomonas aeruginosa exotoxin A (PE25KDEL). The reactivity and toxicity of this immunotoxin with tumor cells were assessed by dot-blot, enzyme-linked immunosorbent assay, and MTT procedures. Results of enzyme-linked immunosorbent assay and dot-blot assay indicated that the immunotoxin recognizes and efficiently binds to EGFR-overexpressing tumor cells. MTT assay showed a specific growth-inhibitory effect of huscFv-PE25 on EGFR-overexpressing A431 cells, without any inhibitory effect on EGFR-negative cells. In conclusion, the results of this study indicated that huscFv-PE25 can recognize and exert an inhibitory effect on EGFR-overexpressing cancer cells, despite its smaller size and lower immunogenicity. This may provide a basis for the development of novel clinical therapeutic agents against EGFR-overexpressing tumor cells.
Collapse
Affiliation(s)
- Bahman Akbari
- aDepartment of Medical Biotechnology, Faculty of Advanced Medical Sciences bDrug Applied Research Center cStudent Research Committee dBiotechnology Research Center eInfection and Tropical Disease Research Center, Tabriz University of Medical Sciences, Tabriz fCardiogenetic Research Laboratory, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Akbari B, Farajnia S, Zarghami N, Mahdieh N, Rahmati M, Khosroshahi SA, Rahbarnia L. Design, expression and evaluation of a novel humanized single chain antibody against epidermal growth factor receptor (EGFR). Protein Expr Purif 2016; 127:8-15. [DOI: 10.1016/j.pep.2016.06.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2016] [Revised: 06/07/2016] [Accepted: 06/07/2016] [Indexed: 10/21/2022]
|
12
|
Baumann P, Hubbuch J. Downstream process development strategies for effective bioprocesses: Trends, progress, and combinatorial approaches. Eng Life Sci 2016; 17:1142-1158. [PMID: 32624742 DOI: 10.1002/elsc.201600033] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2016] [Revised: 03/09/2016] [Accepted: 04/07/2016] [Indexed: 12/26/2022] Open
Abstract
The biopharmaceutical industry is at a turning point moving toward a more customized and patient-oriented medicine (precision medicine). Straightforward routines such as the antibody platform process are extended to production processes for a new portfolio of molecules. As a consequence, individual and tailored productions require generic approaches for a fast and dedicated purification process development. In this article, different effective strategies in biopharmaceutical purification process development are reviewed that can analogously be used for the new generation of antibodies. Conventional approaches based on heuristics and high-throughput process development are discussed and compared to modern technologies such as multivariate calibration and mechanistic modeling tools. Such approaches constitute a good foundation for fast and effective process development for new products and processes, but their full potential becomes obvious in a correlated combination. Thus, different combinatorial approaches are presented, which might become future directions in the biopharmaceutical industry.
Collapse
Affiliation(s)
- Pascal Baumann
- Biomolecular Separation Engineering Karlsruhe Institute of Technology (KIT) Karlsruhe Germany
| | - Jürgen Hubbuch
- Biomolecular Separation Engineering Karlsruhe Institute of Technology (KIT) Karlsruhe Germany
| |
Collapse
|
13
|
Ohtani M, Hikima JI, Jung TS, Kondo H, Hirono I, Takeyama H, Aoki T. Variable domain antibodies specific for viral hemorrhagic septicemia virus (VHSV) selected from a randomized IgNAR phage display library. FISH & SHELLFISH IMMUNOLOGY 2013; 34:724-728. [PMID: 23257206 DOI: 10.1016/j.fsi.2012.11.041] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/12/2012] [Revised: 11/19/2012] [Accepted: 11/30/2012] [Indexed: 06/01/2023]
Abstract
Phage display libraries are used to screen for nucleotide sequences that encode immunoglobulin variable (V) regions that are specific for a target antigen. We previously constructed an immunoglobulin new antigen receptor (IgNAR) phage display library. Here we used this library to obtain an IgNAR V region that is specific for viral hemorrhagic septicemia virus (VHSV). A phage clone (clone 653) was found to be specific for VHSV by the biopanning method. The V region of clone 653 was used to construct a 6 × His tagged recombinant IgNAR-653 V protein (rIgNAR-653) using the Escherichia coli pET system. The rIgNAR-653 protein bound specifically to VHSV, confirming its activity.
Collapse
Affiliation(s)
- Maki Ohtani
- Aquatic Biotechnology Center, College of Veterinary Medicine, Gyeongsang National University, Jinju, Gyeongnam, South Korea
| | | | | | | | | | | | | |
Collapse
|
14
|
Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases. Toxins (Basel) 2012; 4:676-94. [PMID: 23105975 PMCID: PMC3475223 DOI: 10.3390/toxins4090676] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2012] [Revised: 09/04/2012] [Accepted: 09/05/2012] [Indexed: 12/20/2022] Open
Abstract
Diseases caused by chronic inflammation (e.g., arthritis, multiple sclerosis and diabetic ulcers) are multicausal, thus making treatment difficult and inefficient. Due to the age-associated nature of most of these disorders and the demographic transition towards an overall older population, efficient therapeutic intervention strategies will need to be developed in the near future. Over the past decades, elimination of activated macrophages using CD64-targeting immunotoxins has proven to be a promising way of resolving inflammation in animal models. More recent data have shown that the M1-polarized population of activated macrophages in particular is critically involved in the chronic phase. We recapitulate the latest progress in the development of IT. These have advanced from full-length antibodies, chemically coupled to bacterial toxins, into single chain variants of antibodies, genetically fused with fully human enzymes. These improvements have increased the range of possible target diseases, which now include chronic inflammatory diseases. At present there are no therapeutic strategies focusing on macrophages to treat chronic disorders. In this review, we focus on the role of different polarized macrophages and the potential of CD64-based IT to intervene in the process of chronic inflammation.
Collapse
|
15
|
Madhumathi J, Verma RS. Therapeutic targets and recent advances in protein immunotoxins. Curr Opin Microbiol 2012; 15:300-9. [PMID: 22647353 DOI: 10.1016/j.mib.2012.05.006] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2012] [Accepted: 05/14/2012] [Indexed: 12/25/2022]
Abstract
Targeted therapy has replaced the conventional methods of disease management with the advances in recombinant technology and increased understanding of molecular mechanisms of diseases. The immunotoxin strategy for diseases like cancer and a variety of autoimmune disorders has been used successfully in the past since its discovery. Since bacterial, fungal and plant toxins have various limitations like toxicity and immunogenicity, studies on fully humanized immunotoxins have gained attraction recently, which reduced toxicity significantly. Improved methods of antibody engineering have led to the emergence of various new formats of immunotoxins. This review summarizes the target moieties used in immunotoxin constructs in different diseases and describes the recent advances in immunotoxin targeting.
Collapse
Affiliation(s)
- Madhumathi J
- Stem Cell and Molecular Biology Laboratory, Department of Biotechnology, Indian Institute of Technology Madras, Chennai 600036, Tamilnadu, India
| | | |
Collapse
|
16
|
Pentón D, Pérez-Barzaga V, Díaz I, Reytor ML, Campos J, Fando R, Calvo L, Cilli EM, Morera V, Castellanos-Serra LR, Pazos F, Lanio ME, Alvarez C, Pons T, Tejuca M. Validation of a mutant of the pore-forming toxin sticholysin-I for the construction of proteinase-activated immunotoxins. Protein Eng Des Sel 2011; 24:485-93. [PMID: 21296830 DOI: 10.1093/protein/gzr002] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The use of pore-forming toxins from sea anemones (actinoporins) in the construction of immunotoxins (ITs) against tumour cells is an alternative for cancer therapy. However, the main disadvantage of actinoporin-based ITs obtained so far has been the poor cellular specificity associated with the toxin's ability to bind and exert its activity in almost any cell membrane. Our final goal is the construction of tumour proteinase-activated ITs using a cysteine mutant at the membrane binding region of sticholysin-I (StI), a cytolysin isolated from the sea anemone Stichodactyla helianthus. The mutant and the ligand moiety would be linked by proteinase-sensitive peptides through the StI cysteine residue blocking the toxin binding region and hence the IT non-specific killing activity. To accomplish this objective the first step was to obtain the mutant StI W111C, and to evaluate the impact of mutating tryptophan 111 by cysteine on the toxin pore-forming capacity. After proteolysis of the cleavage sequence, a short peptide would remain attached to the toxin. The next step was to evaluate whether this mutant is able to form pores even with a residual peptide linked to cysteine 111. In this work we demonstrated that (i) StI W111C shows pore-forming capacity in a nanomolar range, although it is 8-fold less active than the wild-type recombinant StI, corroborating the previously reported importance of residue 111 for the binding of StI to membranes, and (ii) the mutant is able to form pores even with a residual seven-residue peptide linked to cysteine 111. In addition, it was demonstrated that binding of a large molecule to cysteine 111 renders an inactive toxin that is no longer able to bind to the membrane. These results validate the mutant StI W111C for its use in the construction of tumour proteinase-activated ITs.
Collapse
Affiliation(s)
- David Pentón
- Faculty of Biology, Center for Protein Studies, University of Havana, Calle 25 #455 e/ J e I, Vedado, Ciudad de La Habana, Cuba
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Eiberle MK, Jungbauer A. Technical refolding of proteins: Do we have freedom to operate? Biotechnol J 2010; 5:547-59. [DOI: 10.1002/biot.201000001] [Citation(s) in RCA: 81] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
18
|
Zhang T, Wang CY, Zhang W, Gao YW, Yang ST, Wang TC, Zhang RZ, Qin C, Xia XZ. Generation and characterization of a fusion protein of single-chain fragment variable antibody against hemagglutinin antigen of avian influenza virus and truncated protamine. Vaccine 2010; 28:3949-55. [PMID: 20382243 DOI: 10.1016/j.vaccine.2010.03.045] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2010] [Revised: 03/23/2010] [Accepted: 03/25/2010] [Indexed: 02/07/2023]
Abstract
The hemagglutinin antigen (HA) of avian influenza virus (AIV) is an immunogen abundant on the surfaces of infected cells, and can be used as a target for specific antibodies to clear viral infection. Protamine has been demonstrated to deliver DNA into cells effectively. Accordingly, a fusion protein of anti-HA single-chain fragment variable (scFv) and truncated protamine (tP) may be used as a vehicle for delivering the anti-AIV siRNA into the AIV-infected cells for gene therapy. To test this hypothesis, we constructed a novel recombinant plasmid, pET28-scFv-tP, by connecting the genes for anti-H5N1 AIV HA-specific scFv with synthesized oligonucleotides encoding the 22 amino acids of human tP and a linker. Furthermore, the recombinant scFV-tP was expressed and purified, with a yield of 7-8mg of scFv-tP and a purity of >92% from 1L of bacterial culture. Characterization of its bioactivity revealed that scFv-tP recognized HA, similar to its scFv control, in a dose-dependent manner and that the scFv-tP, but not its scFv control, bound to DNA and delivered plasmid and oligonucleotide DNA into the AIV-infected MDCK cells effectively. More importantly, transfection with the mixture of the scFv-tP and plasmid for the NP-specific siRNA significantly inhibited the replication of AIV in MDCK cells, as compared with that transfection with the scFv-plasmid mixture, even with the plasmid in liposome. Our data demonstrated that the recombinant scFv-tP retained the functions of both scFv and tP, and might be potentially used for delivering genetic materials for targeting therapy of AIV infection in vivo.
Collapse
Affiliation(s)
- Tao Zhang
- Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Abe R, Kudou M, Tanaka Y, Arakawa T, Tsumoto K. Immobilized metal affinity chromatography in the presence of arginine. Biochem Biophys Res Commun 2009; 381:306-10. [DOI: 10.1016/j.bbrc.2009.01.054] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2008] [Accepted: 01/13/2009] [Indexed: 11/28/2022]
|
20
|
Tejuca M, Anderluh G, Dalla Serra M. Sea anemone cytolysins as toxic components of immunotoxins. Toxicon 2009; 54:1206-14. [PMID: 19268683 DOI: 10.1016/j.toxicon.2009.02.025] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
The use of membrane active toxins as toxic moieties in the construction of immunotoxins (ITs) is an attractive alternative to overcome some of the problems of classical ITs since these new conjugates are based in the use of a different mechanism of killing undesired cells. Pore-forming cytolysins from sea anemones were used in the construction of ITs targeted to different cell types including tumour cell lines and the parasite Giardia duodenalis. The results obtained support the feasibility of directing these cytolysins to the surface of the cancer cells or the parasite through their conjugation to monoclonal antibodies recognizing tumour-associated or parasite antigens, respectively. However the main problem with the IT constructed in this fashion is the lack of specificity associated with the toxin moiety. An approach designed to overcome this limitation was the construction of inactive cytolysin with built-in biological "trigger" that renders the toxin active in the presence of tumour-specific proteinases. This construction is considered as a proof of concept to demonstrate the feasibility of such activation systems in the construction of ITs based on pore-forming cytolysins from sea anemones with reduced unspecific activity. The future prospects of the use of the N-terminal region of actinoporins for construction of IT is also described.
Collapse
Affiliation(s)
- Mayra Tejuca
- Centro de Estudios de Proteínas y Departamento de Bioquímica, Facultad de Biologia, Universidad de La Habana, Calle 25 #455 e/ J e I, Vedado, Ciudad de La Habana, Cuba.
| | | | | |
Collapse
|
21
|
High-level expression of a functional humanized anti-CTLA4 single-chain variable fragment antibody in Pichia pastoris. Appl Microbiol Biotechnol 2009; 82:41-8. [DOI: 10.1007/s00253-008-1744-3] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2008] [Revised: 10/02/2008] [Accepted: 10/02/2008] [Indexed: 10/21/2022]
|
22
|
Yajima W, Rahman MH, Das D, Suresh MR, Kav NNV. Detection of Sclerotinia sclerotiorum using a monomeric and dimeric single-chain fragment variable (scFv) antibody. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2008; 56:9455-9463. [PMID: 18800799 DOI: 10.1021/jf801768g] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Sclerotinia sclerotiorum (Lib.) de Bary is a phytopathogenic fungus capable of causing significant yield losses in numerous crops, including canola, in which the fungus causes sclerotinia stem rot. Immunological detection methods to rapidly determine the presence of S. sclerotiorum on plants may provide growers with a viable diagnostic tool to aid with fungicide use decisions. This paper discusses the generation of a monomeric and dimeric single-chain, variable fragment (scFv) antibody with affinity for S. sclerotiorum using phage display technology. The bacterially expressed and purified scFv is shown to bind S. sclerotiorum with some cross-reactivity with the closely related phytopathogen Botrytis cinerea (Pers.:Fr.). The dimeric scFv displayed improved binding to the fungus as compared to the monomer and could detect the presence of mycelia in inoculated canola petals. To the authors' knowledge, this is the first report of a scFv dimer with affinity for S. sclerotiorum that has the potential for use in the development of a new diagnostic test.
Collapse
Affiliation(s)
- William Yajima
- Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta, Canada T6G 2P5
| | | | | | | | | |
Collapse
|
23
|
Kumar P, Ban HS, Kim SS, Wu H, Pearson T, Greiner DL, Laouar A, Yao J, Haridas V, Habiro K, Yang YG, Jeong JH, Lee KY, Kim YH, Kim SW, Peipp M, Fey GH, Manjunath N, Shultz LD, Lee SK, Shankar P. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008; 134:577-86. [PMID: 18691745 PMCID: PMC2943428 DOI: 10.1016/j.cell.2008.06.034] [Citation(s) in RCA: 457] [Impact Index Per Article: 28.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2008] [Revised: 05/08/2008] [Accepted: 06/12/2008] [Indexed: 11/17/2022]
Abstract
Evaluation of the therapeutic potential of RNAi for HIV infection has been hampered by the challenges of siRNA delivery and lack of suitable animal models. Using a delivery method for T cells, we show that siRNA treatment can dramatically suppress HIV infection. A CD7-specific single-chain antibody was conjugated to oligo-9-arginine peptide (scFvCD7-9R) for T cell-specific siRNA delivery in NOD/SCIDIL2rgamma-/- mice reconstituted with human lymphocytes (Hu-PBL) or CD34+ hematopoietic stem cells (Hu-HSC). In HIV-infected Hu-PBL mice, treatment with anti-CCR5 (viral coreceptor) and antiviral siRNAs complexed to scFvCD7-9R controlled viral replication and prevented the disease-associated CD4 T cell loss. This treatment also suppressed endogenous virus and restored CD4 T cell counts in mice reconstituted with HIV+ peripheral blood mononuclear cells. Moreover, scFvCD7-9R could deliver antiviral siRNAs to naive T cells in Hu-HSC mice and effectively suppress viremia in infected mice. Thus, siRNA therapy for HIV infection appears to be feasible in a preclinical animal model.
Collapse
Affiliation(s)
- Priti Kumar
- Immune Disease Institute and Department of Pediatrics, Harvard Medical School, Boston, MA, 02115, USA
| | - Hong-Seok Ban
- Department of Bioengineering and Hanyang Fusion Materials Program,, Hanyang University, Seoul, 133-791, Korea
| | - Sang-Soo Kim
- Immune Disease Institute and Department of Pediatrics, Harvard Medical School, Boston, MA, 02115, USA
| | - Haoquan Wu
- Immune Disease Institute and Department of Pediatrics, Harvard Medical School, Boston, MA, 02115, USA
| | - Todd Pearson
- Department of Medicine, Division of Diabetes, University of Massachusetts Medical School, Worcester, 01605, MA, USA
| | - Dale. L. Greiner
- Department of Medicine, Division of Diabetes, University of Massachusetts Medical School, Worcester, 01605, MA, USA
| | - Amale Laouar
- Immune Disease Institute and Department of Pediatrics, Harvard Medical School, Boston, MA, 02115, USA
| | - Jiahong Yao
- Immune Disease Institute and Department of Pediatrics, Harvard Medical School, Boston, MA, 02115, USA
| | - Viraga Haridas
- Immune Disease Institute and Department of Pediatrics, Harvard Medical School, Boston, MA, 02115, USA
| | - Katsuyoshi Habiro
- Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02129, USA
| | - Yong-Guang Yang
- Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02129, USA
| | - Ji-Hoon Jeong
- Center for Controlled Chemical Delivery, Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT, 84112, USA
| | - Kuen-Yong Lee
- Department of Bioengineering and Hanyang Fusion Materials Program,, Hanyang University, Seoul, 133-791, Korea
| | - Yong-Hee Kim
- Department of Bioengineering and Hanyang Fusion Materials Program,, Hanyang University, Seoul, 133-791, Korea
| | - Sung Wan Kim
- Center for Controlled Chemical Delivery, Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT, 84112, USA
| | - Matthias Peipp
- Division of Stem Cell Transplantation and Immunotherapy, Christian-Albrechts-University, Kiel, Germany
| | - Georg H. Fey
- University of Erlangen, D 91058, Erlangen, Germany
| | - N Manjunath
- Immune Disease Institute and Department of Pediatrics, Harvard Medical School, Boston, MA, 02115, USA
| | | | - Sang-Kyung Lee
- Department of Bioengineering and Hanyang Fusion Materials Program,, Hanyang University, Seoul, 133-791, Korea
| | - Premlata Shankar
- Immune Disease Institute and Department of Pediatrics, Harvard Medical School, Boston, MA, 02115, USA
| |
Collapse
|
24
|
Nakakido M, Tanaka Y, Mitsuhori M, Kudou M, Ejima D, Arakawa T, Tsumoto K. Structure-based analysis reveals hydration changes induced by arginine hydrochloride. Biophys Chem 2008; 137:105-9. [PMID: 18725174 DOI: 10.1016/j.bpc.2008.07.009] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2008] [Revised: 07/28/2008] [Accepted: 07/30/2008] [Indexed: 11/29/2022]
Abstract
Arginine hydrochloride has been used to suppress protein aggregation during refolding and in various other applications. We investigated the structure of hen egg-white lysozyme (HEL) and solvent molecules in arginine hydrochloride solution by X-ray crystallography. Neither the backbone nor side-chain structure of HEL was altered by the presence of arginine hydrochloride. In addition, no stably bound arginine molecules were observed. The number of hydration water molecules, however, changed with the arginine hydrochloride concentration. We suggest that arginine hydrochloride suppresses protein aggregation by altering the hydration structure and the transient binding of arginine molecules that could not be observed.
Collapse
Affiliation(s)
- Makoto Nakakido
- Department of Medical Genome Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa 277-8562, Japan
| | | | | | | | | | | | | |
Collapse
|
25
|
Geng S, Chang H, Qin W, Li Y, Feng J, Shen B. Overexpression, Effective Renaturation, and Bioactivity of Novel Single‐Chain Antibodies Against TNF‐α. Prep Biochem Biotechnol 2007; 38:74-86. [DOI: 10.1080/10826060701774379] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
26
|
Daniels TR, Ng PP, Delgado T, Lynch MR, Schiller G, Helguera G, Penichet ML. Conjugation of an anti–transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells. Mol Cancer Ther 2007; 6:2995-3008. [DOI: 10.1158/1535-7163.mct-07-0330] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|